Latest Breaking News On - John neylan - Page 3 : comparemela.com

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/ Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion s AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI). This indication is part of the ANG-3777 license agreement both parties signed in November 2020. CSA-AKI is a frequent complication of cardiac bypass surgery seen in about one third of patients and is associated with prolonged hospitalization, progressive kidney failure, and an increased risk of death, commented Dr. John Neylan, Angion s Senior Vice President and Chief Medical Officer. Currently, there are no approved therapies to prevent this serious condition. Thi

United statesJohn neylanVifor pharmaJulien vignotKlaus henning jensenNathalie ponnierSwiss stock exchangeExchange commission onGlobal head corporate communicationsAngion biomedica corpSwiss exchangeExchange commissionVifor pharma groupSinovant sciencesFresenius medical careAngion biomedica